RPL17 and melanoma: To investigate the relationship between macrophage subtypes in tumors and the efficacy of immune-targeted therapy, we conducted GSEA analysis using specific signature genes of different macrophage subtypes between patients with progressive disease (PD) and patients with complete response (CR) or partial response (PR) upon anti-PD-1 treatment for melanoma, NSCLC, and thymic carcinoma.